GenTraceDx Investor Overview
Precision Oncology Is Moving Beyond Static Testing
- New therapies, biomarkers, and clinical trials emerge continuously
- Most systems still deliver static, one-time reports
- Clinical relevance degrades over time
GenTraceDx is built for a new model: continuously updating clinical intelligence.
Static Testing Breaks Over Time
- Most tests rely on fixed gene panels
- Results are delivered once and quickly become outdated
- New therapies and trials are not reflected
- Clinicians must manually track changes
Result: many patients receive no actionable findings, even as new options continue to emerge.
A New Category
- Multiomic (DNA + RNA) rather than panel-based
- Longitudinal rather than one-time
- Continuously updating rather than static
- Built for real-world clinical deployment
GenTraceDx is not an incremental improvement. It is a new model for precision oncology.
Canada-Wide National Clinical Pilot
- Supported by Genome Canada (Genomics Applications Partnership Program — GAPP)
- Supported by Genome British Columbia
- Developed in collaboration with Canada’s Michael Smith Genome Sciences Centre
- Led by Genetrack Biolabs, a Canadian leader in regulated diagnostics
Canada-wide clinical deployment through a 500-patient national pilot
- Pilot launch: Fall 2026
- Pre-enrollment: Now open
Real-World Clinical Impact
- Standard panel testing may yield no actionable findings
- Multiomic analysis can reveal additional therapeutic opportunities
- Findings can inform further treatment planning
Broader profiling and reinterpretation can change clinical decision-making.
Built by Proven Operators and World-Class Science
Genetrack Biolabs
- 25+ years in regulated diagnostics
- CAP, CLIA, AABB, and ISO accreditation
- National-scale operational and deployment experience
Michael Smith Genome Sciences Centre
- International leader in cancer genomics
- Deep expertise in translational oncology and clinical sequencing
Ready for Clinical Deployment
- Clinic-ready sample collection kits
- Established laboratory and logistics workflows
- Secure clinician and patient platforms
- Regulatory and quality systems in place
Designed for real-world use.
A Large Market — With a Structural Gap
- Strong validation from existing commercial platforms
- Continued growth in targeted therapies and biomarker-driven care
- Increasing demand for more clinically useful genomic interpretation
Opportunity: continuously updating clinical intelligence.
Multiple Value Streams
Per-case testing
Longitudinal reinterpretation
Clinical trial matching
Pharmaceutical and research partnerships
The science is advancing quickly. Clinical infrastructure has not kept pace.
GenTraceDx is positioned at this transition.
The Inflection Point
Rapid growth in targeted therapies
Increasing clinical trial complexity
Expanding genomic data generation
Rising demand for more effective precision oncology tools
The science is advancing quickly. Clinical infrastructure has not kept pace.
GenTraceDx is positioned at this transition.
Target Metrics
| Metric | Target by Year 3 |
|---|---|
| Annual Tests Run | 200,000+ |
| Revenue Potential | $100M–$150M+ CAD annually |
| Cost per Test | $900–$1,200 CAD (clinical pricing) |
| Gross Margin | 60%+ (projected at scale) |
| Export Market Readiness | U.S., U.K., EU, Australia |
Early Entry Into a New Category
Diagnostic testing
Continuously updating clinical intelligence
Opportunity: continuously updating clinical intelligence.
Investor & Strategic Partnerships
Due to the nature of ongoing funding discussions, detailed materials are shared selectively.
If you are interested in learning more, we welcome the opportunity to connect.